Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently Amended) An aqueous formulation of a therapeutic agent comprising:

DO NOT ENTER: /JK/

rapamycin in a pharmaceutically effective dosage;

ethanol in a residual concentration of about 4.7 1.57 percent by weight; vitamin E TPGS in an amount of about 4.3 6.55 percent by weight; and water in an amount of about 92 90.51 percent by weight, the rapamycin, vitamin E TPGS and water forming a stable aqueous solution, thereby remaining a solution without precipitation, the stable aqueous formulation comprising a final solution of rapamycin in the range from about 4 mg/ml to about 15 mg/ml.

- 2. (Cancelled)
- 3. (Cancelled)
- 4. (Original) The liquid formulation according to claim 3, wherein the rapamycin comprises sirolimus.
- 5. (Original) The liquid formulation according to claim 3, wherein the rapamycin comprises CCI-779.
 - 6. (Cancelled)

- 7. (Cancelled)
- 8. (Cancelled)
- 9. (Withdrawn) A method for the treatment of vascular disease comprising the administration of a liquid formulation of rapamycin proximate the disease site.
- 10. (Withdrawn) The method for the treatment of vascular disease according to claim 9, wherein the liquid formulation of rapamycin comprises rapamycin in a pharmaceutically effective dosage and one or more pharmaceutically acceptable solubility enhancers.